This study evaluates an intranasal subunit vaccine based on albumin-antigen fusion to induce systemic and mucosal immunity. Using the HSA/hFcRn mouse model, the vaccine elicited robust systemic IgG and mucosal IgA responses, providing protection against SARS-CoV-2 and influenza A virus. The model allowed precise evaluation of FcRn-mediated antibody transport and persistence.
Albumin-based intranasal vaccination induced strong systemic and mucosal antibody responses and superior protection compared to standard mRNA and non-albumin nasal vaccines.
Humanized double Knockin HSA/hFcRn mouse model developed by genOway, expressing human serum albumin and FcRn for accurate pharmacokinetic and immunogenicity studies.
Respiratory viruses, Intranasal vaccine, Mucosal immunity, SARS-CoV-2, Influenza, FcRn pharmacology
Humanized Knockin model, HSA/hFcRn expression, Albumin fusion vaccine, Intranasal delivery
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
